Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The company's CEO, Marino Garcia, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. Interested parties can access a live webcast of the presentation through the 'News and Events' section of the Investors page on the Dianthus Therapeutics website.
Dianthus Therapeutics (Nasdaq: DNTH), una azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie avanzate con anticorpi per malattie autoimmuni gravi, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare.
Il CEO dell'azienda, Marino Garcia, presenterà una panoramica aziendale mercoledì 15 gennaio 2025, alle 9:00 PST / 12:00 EST a San Francisco. Le parti interessate possono accedere a una diretta web della presentazione attraverso la sezione 'News and Events' della pagina Investitori sul sito web di Dianthus Therapeutics.
Dianthus Therapeutics (Nasdaq: DNTH), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias avanzadas con anticuerpos para enfermedades autoinmunes severas, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare.
El CEO de la compañía, Marino Garcia, ofrecerá una presentación sobre la empresa el miércoles 15 de enero de 2025, a las 9:00 a.m. PST / 12:00 p.m. EST en San Francisco. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección 'News and Events' en la página de Inversores del sitio web de Dianthus Therapeutics.
Dianthus Therapeutics (Nasdaq: DNTH), 심각한 자가면역 질환을 위한 고급 항체 보완 치료제를 개발하는 임상 단계의 생명공학 회사, 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 CEO인 마리노 가르시아는 2025년 1월 15일 수요일, 오전 9시 PST / 오후 12시 EST에 샌프란시스코에서 회사 개요 발표를 진행할 예정입니다. 관심 있는 당사자는 Dianthus Therapeutics 웹사이트의 투자자 페이지 '뉴스 및 이벤트' 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다.
Dianthus Therapeutics (Nasdaq: DNTH), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies avancées par anticorps pour des maladies auto-immunes sévères, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare.
Le PDG de l'entreprise, Marino Garcia, fera une présentation sur la société mercredi 15 janvier 2025, à 9h00 PST / 12h00 EST à San Francisco. Les parties intéressées peuvent accéder à une diffusion en direct de la présentation via la section 'News and Events' de la page Investisseurs sur le site de Dianthus Therapeutics.
Dianthus Therapeutics (Nasdaq: DNTH), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung fortschrittlicher Antikörper-Komplementtherapien zur Behandlung schwerer Autoimmunerkrankungen konzentriert, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare bekannt gegeben.
Der CEO des Unternehmens, Marino Garcia, wird am Mittwoch, den 15. Januar 2025, um 9:00 Uhr PST / 12:00 Uhr EST in San Francisco eine Unternehmenspräsentation halten. Interessierte Parteien können über den Abschnitt 'News and Events' auf der Investorenseite der Website von Dianthus Therapeutics auf einen Live-Stream der Präsentation zugreifen.
- None.
- None.
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When is Dianthus Therapeutics (DNTH) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Dianthus Therapeutics' (DNTH) J.P. Morgan Healthcare Conference presentation?
What will be discussed at Dianthus Therapeutics' (DNTH) J.P. Morgan Healthcare Conference presentation?
What is Dianthus Therapeutics' (DNTH) main focus in drug development?
